Cancer treatment

#Cancer treatment #Cell therapy

Virtual care to support patients receiving cell therapies 

Virtual oncology care platform Reimagine Care and The Center for Cancer and Blood Disorders have partnered to support patients receiving advanced cell therapies.  The Advanced Therapy Management (ATM) programme provides a model designed to support outpatient post-infusion monitoring and management of CAR-T and other advanced oncology therapies.    The expansion builds on… Read More

#News

Nucleolus of the cell
#Cancer treatment #Oncology #RNA #Texas A&M University Health Science Center

Researchers identify RNA linked to cancer survival

Researchers at the Texas A&M University Health Science Center have identified a novel RNA molecule that plays a crucial role in preserving the integrity of a key cellular structure, nucleolus.  This research reveals an RNA molecule that regulates key cellular functions without turning into protein, thus functioning… Read More

#Cancer Research #Editor's Choice #News

Nasal spray
#Cancer treatment #Cervical cancer #HPV #Immunology / Virology & Vaccines #Oncology

Scientists create nasal vaccine for treating cervical cancer

Researchers at Chiba University in Japan have developed a new nasal therapeutic vaccine as a non-invasive treatment option for cervical cancer.   Cervical cancer is primarily caused by the human papillomavirus (HPV), but there are no approved therapeutic medicines to treat existing infections or HPV-associated cancers. … Read More

#Cancer Research #Editor's Choice #News

#Cancer treatment #Intensity Therapeutics #Oncology #Phase II trial #Solid tumours

Intratumoral injection drives local and systemic anti-cancer activity

eBioMedicine, a Lancet Discovery Science journal, has published Intensity Therapeutics’ Phase I/II IT-01 clinical study manuscript for the treatment of metastatic or refractory cancers.   According to the data, in heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Cancer therapeutics #Cancer treatment #Interview #Oncology

Reducing cancer side effects through targeted therapies

Harry Palmer, Royal Commission of 1851 Industrial Fellow and PhD at University of Strathclyde, shares with DDW’s Megan Thomas how antibody-drug conjugates (ADCs) are revolutionising cancer treatment by offering targeted therapies with improved efficacy and reduced side effects, while addressing challenges in their development and paving the way for future… Read More

#Cancer Research #Exclusive Content

#Cancer drug targets #Cancer therapeutics #Cancer treatment #Oncology

New DDW Highlights podcast: 22 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we are halfway through Breast Cancer Awareness Month, our news highlights this week… Read More

#News

#Cancer drug targets #Cancer therapeutics #Cancer treatment #Oncology

This week in drug discovery (14-18 October) 

News round-up for 14-18 October by DDW Senior Digital Content Editor Diana Spencer. As we are halfway through Breast Cancer Awareness Month, our news highlights this week focus on studies that could advance the treatment of cancer in the future, including a new understanding of cancer drug… Read More

#News

Simon and Vanessa Conn
#Cancer treatment #circular RNAs #Flinders University #Oncology #Personalised medicine #RNA

Harnessing circRNAs could “change the landscape” of cancer therapy

Circular RNAs (circRNAs) have “remarkable potential” to improve cancer treatment and patient outcomes within the next five to 10 years, according to a new study by Flinders University in Australia. The research was led by Senior Researcher Dr Vanessa Conn and Professor Simon Conn, who leads… Read More

#Cancer Research #Editor's Choice #News

Cancer cells
#ASCO #Cancer therapeutics #Cancer treatment #Cancer vaccine #Oncology

Five 2024 breakthroughs in cancer drug research

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease. Lorbrena advances… Read More

#Cancer Research #News #Trending News

#Bispecific Antibodies #Cancer treatment #Checkpoint inhibitor therapies #Clinical trials #Solid tumours

Phase I trial for first-in-class bispecific antibody for cancer

Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.  The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoural activity of OT-A201.   The study is a European multicentre and… Read More

#Cancer Research #News

Stomach pain
#Cancer treatment #Chemotherapy #Napo Pharmaceuticals #Oncology #Preclinical investigations #Puma Biotechnology

Prescription drug could prevent cancer therapy-related diarrhoea

A study in dogs has shown that crofelemer can provide symptomatic relief of diarrhoea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI) neratinib (Nerlynx). Puma Biotechnology’s Nerlynx is a pan HER TKI indicated for the extended adjuvant treatment of adult… Read More

#Cancer Research #News

Cytokine release syndrome
#Cancer treatment #Clinical trials #Haematology #Immunotherapy #Institute of Cancer Research #Poolbeg Pharma

Treatment potential for immunotherapy-induced CRS

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS).   POLB 001 demonstrated efficacy in reducing… Read More

#Cancer Research #News

Theranostic radiopharmaceuticals
#Ariceum Therapeutics #Cancer treatment #Radiopharmaceuticals

In Conversation With: Manfred Ruediger, CEO of Ariceum

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Manfred Ruediger, CEO of… Read More

#News

Cancer research
#AACR #Cancer research #Cancer treatment

AACR Cancer Progress Report with spotlight on cancer immunotherapy 

On 13 September 2023, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2023: Advancing the Frontiers of Cancer Science and Medicine.   This report chronicles how basic, translational, clinical cancer research, and cancer-related population sciences — supported by federal investments in the National Institutes of Health… Read More

#Business & Investment #Cancer Research #News #Regulatory

Endometrial cancer
#Cancer treatment #FDA #GSK #Oncology #Regulatory

FDA approves Jemperli plus chemo in endometrial cancer

GSK’s Jemperli (dostarlimab) has been approved in the US plus chemotherapy as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The US Food and Drug Administration (FDA) approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed… Read More

#News #Regulatory